NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is testing PrimeC in people with amyotrophic lateral sclerosis (ALS). News of trial findings being expected in December follows the dosing of a final patient in the randomized portion of…
The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for amyotrophic lateral sclerosis (ALS). This Series A financing round is essentially the next round of funding after seed money was used to rapidly develop the investigational treatment. Both rounds…
A person’s degree of exposure to multiple environmental pollutants — reflected by their presence in the blood — may be used to predict amyotrophic lateral sclerosis (ALS) risk and survival, according to new research. Greater exposure to these chemicals was associated with increased odds of an individual developing ALS,…
The genetic activity of certain brain cells, namely excitatory neurons and astrocytes, is altered in people with amyotrophic lateral sclerosis (ALS) caused by mutations in the C9ORF72 gene, a study reports. The data reveal the distinct molecular mechanisms that may lead to disease progression in people with such mutations, which…
Is it feasible to remotely collect health data from people with amyotrophic lateral sclerosis (ALS)? And would doing so help in gauging disease progression among patients? That’s what a remote observational study called ALS Go-Digital is now trying to assess. If validated, the approach could pave the way to…
Rapamycin, an approved medication used to prevent organ rejection after a kidney transplant, didn’t increase the number of regulatory T-cells in adults with amyotrophic lateral sclerosis (ALS) who are taking part in a Phase 2 clinical trial. Along with not meeting its primary goal, RAP-ALS (NCT03359538) also…
Pregnancy can worsen the progression of amyotrophic lateral sclerosis (ALS), regardless of whether symptom onset occurs before or during pregnancy, according to a review study. Still, most of the cases reviewed showed that ALS did not affect a woman’s ability to give birth, naturally or by cesarean section, or…
People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable quality of life and low stress levels, according to a survey conducted across nine European countries. When asked about new drug development, participants most commonly prioritized treatments that slow…
A man with amyotrophic lateral sclerosis (ALS) was able to control external devices — lighting and a TV — with only his thoughts using a brain-computer interface (BCI) device, according to a recent study. Called Cortical Communication (CortiCom), the BCI system learns to predict a person’s intended action by…
Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory therapy ZYIL1 in people with amyotrophic lateral sclerosis (ALS). The company announced it has received clearance for the clinical trial (NCT05981040) from India’s Central Drugs Standard Control Organization…
Get regular updates to your inbox.